Willis C. Lee - Apr 4, 2022 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)

Role: Director & COO, Director
Signature: Willis C. Lee
Stock symbol: EMMA
Transactions as of: Apr 4, 2022
Transactions value $: $13,514
Form type: 4
Date filed: 4/12/2022, 03:59 PM
Previous filing: Feb 28, 2022
Next filing: Jun 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EMMA	Common stock, $0.001 par value	Purchase	$3.14K	+3.2K	+1.36%	$0.98	238K	Apr 4, 2022	By Fidelity Traditional IRA FBO Willis C. Lee
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1.33K	+1.4K	+0.59%	$0.95	240K	Apr 6, 2022	By Fidelity Traditional IRA FBO Willis C. Lee
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1.22K	+1.6K	+0.67%	$0.76	241K	Apr 8, 2022	By Fidelity Traditional IRA FBO Willis C. Lee	F1
transaction	EMMA	Common stock, $0.001 par value	Purchase	$7.83K	+8.9K	+3.3%	$0.88	279K	Apr 11, 2022	Direct	F2
holding	EMMA	Common stock, $0.001 par value						1.9K	Apr 4, 2022	By Fidelity Roth IRA FBO Willis C. Lee

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.75 to $0.78, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.89, inclusive.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.75 to $0.78, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.89, inclusive.